Related by context. All words. (Click for frequent words.) 75 ACR# responses 72 mg BID 72 ACR Pedi 71 sustained virologic response 71 plus methotrexate 71 sUA 71 CIMZIA TM 71 sustained virological response 71 mcg albinterferon alfa 2b 70 complete cytogenetic response 70 CCyR 70 serologically active patients 70 ACR# [002] 70 SVR# 70 MCyR 70 HBeAg seroconversion 70 achieved ACR# 70 DAS# remission 70 evaluable subjects 70 complete cytogenetic 69 Index CDAI 69 Crohn Disease Activity 69 SELENA SLEDAI score 69 lopinavir r arm 69 undetectable HCV RNA 69 PASI scores 69 oxycodone CR 69 Psoriasis Area 68 CDAI score 68 ACTEMRA TM 68 cytogenetic response 68 mg BID dose 68 adalimumab 68 mcg BID 68 peginterferon alfa 2a 68 virologic response 68 annualized relapse 68 undetectable HBV DNA 68 ACR# ACR# 68 seroprotection 68 CIMZIA ™ 68 log# IU mL 67 plus dexamethasone 67 8mg/kg 67 CR nPR 67 tipranavir r 67 EDSS score 67 clinically meaningful improvement 67 mg QD 67 lumbar spine BMD 67 CR CRu 66 mg ustekinumab 66 adefovir treated 66 MADRS score 66 mg TID 66 mg kg dose 66 seropositive patients 66 undetectable viral load 66 tapentadol ER 66 Flu Cy 66 mg qd 66 receiving golimumab 66 placebo p 66 Solid Tumors criteria 66 SLE Responder Index 66 achieved PASI 66 log# reduction 66 RECIST Response Evaluation Criteria 66 XIENCE V PROMUS Stent 66 baseline HbA1c 65 methotrexate monotherapy 65 definite stent thrombosis 65 HAQ DI 65 REYATAZ r arm 65 serum urate 65 certolizumab 65 Montgomery Asberg Depression 65 -#.# log# 65 mcg Albuferon 65 Free Survival PFS 65 placebo p = 65 mcg QD 65 FluCAM 65 #mg BID [001] 65 binary restenosis 65 FOLFOX4 65 Scale EDSS 65 % Confidence Interval 65 Hb A1C 65 YMRS 65 dapagliflozin plus 65 chlorambucil 65 oral allopurinol 65 virological response 64 plus MTX 64 IRLS score 64 DAS# CRP 64 R# #mg BID 64 DAS# [002] 64 -#.# mg dL [002] 64 HBeAg negative patients 64 mTSS 64 lopinavir r 64 PREZISTA r arm 64 HDRS 64 bortezomib refractory 64 Doxil ® 64 Capacity FVC 64 ARB telmisartan 64 #mg dose [002] 64 mg dose 64 Expanded Disability Status 64 Lupuzor ™ 64 detectable HCV RNA 64 achieved CCyR 64 achieved statistical significance 64 belimumab 64 primary efficacy endpoint 64 Sustained virologic response 64 Timed Walk 64 achieving PASI 64 CIMZIA TM certolizumab pegol 64 postdose 64 CANCIDAS 64 tolvaptan 64 Severity Index PASI 64 solifenacin 64 log# copies mL 64 alanine aminotransferase ALT 64 Ishak fibrosis score 63 gadolinium enhancing lesions 63 Pharmacokinetic parameters 63 pCR 63 morphometric vertebral fractures 63 PREZISTA r 63 HAM D# scores 63 Engerix B 63 3mg/kg 63 evaluable patients 63 relapsed MM 63 virologic failure 63 adjunctive placebo 63 4mg/kg 63 peginterferon alfa 2a #KD 63 Scale EDSS score 63 QTcF 63 endoscopic remission 63 serum HBV DNA 63 cEVR 63 LEXIVA r 63 Response Evaluation Criteria 63 serologically active SLE 63 ARCOXIA 63 desvenlafaxine succinate 63 CDAI 63 certolizumab pegol 63 Kaplan Meier estimates 63 ACZ# 63 ULORIC 63 REMICADE monotherapy 63 serum phosphate 63 liver histology 63 virologic suppression 63 response CCyR 63 mcg kg 63 plasma HCV RNA 63 biochemical relapse 63 microbiological eradication 63 Ejection Fraction 63 degarelix 63 ALVESCO 63 remission CR 62 CRp 62 BARACLUDE r 62 RECIST criteria 62 HBeAg positive patients 62 statistically significant p = 62 FOLFOX6 62 placebo dexamethasone 62 pegylated interferon alfa 62 Pegasys plus Copegus 62 trough FEV1 62 adefovir 62 FDA defined valvulopathy 62 BPRS PSS 62 salmeterol fluticasone 62 complete remissions 62 TLUS 62 mcg dose 62 -#.# mg dL [001] 62 baseline LDH 62 imipenem 62 ug kg 62 NIHSS 62 rapid virologic response 62 EDSS scores 62 A1c levels 62 tolterodine ER 62 mg kg belimumab 62 median PFS 62 PSA nadir 62 FOLPI 62 mg/m2 dose 62 IPSS 62 APTIVUS r 62 MARINOL R 62 HbA 1c 62 moderate renal impairment 62 piperacillin tazobactam 62 A1C levels 62 experienced virologic failure 62 evaluable 62 comparator arm 62 mucosal healing 62 SSRI SNRI 62 mg/m2/day 62 anemia hemoglobin 62 IFN α 62 confirmed CCyR 62 ADCS CGIC 62 PANSS total 62 timepoint 62 Pegasys ® 62 clodronate 62 log# 62 tocilizumab 62 placebo fluoxetine 62 viral kinetics 62 PegIFN RBV 62 NIH CPSI 62 splenectomized patients 62 microgram kg 62 undetectable viral 62 mRCC 62 PROMACTA 62 Median PFS 62 octreotide LAR 62 patients evaluable 61 achieved sustained virologic 61 pegylated interferon alpha 61 free survival PFS 61 BARACLUDE ® 61 fosamprenavir 61 plus prednisone 61 elevated ALT 61 alemtuzumab treated 61 serum testosterone 61 induction regimen 61 IU ml 61 Aptivus ® 61 % CI #.#-#.# [003] 61 prospectively defined 61 fluticasone salmeterol 61 HSCT 61 corticosteroid dose 61 #mg QD [002] 61 severe neutropenia 61 discontinuations due 61 peg interferon 61 ADAS cog 61 glycated hemoglobin levels 61 FOLFOX 61 oral diclofenac 61 virologic response EVR 61 DAS# scores 61 SUVmax 61 mcg doses 61 PRADAXA #mg 61 BENICAR HCT 61 tirofiban 61 doripenem 61 Rating Scale MADRS 61 fasting plasma glucose FPG 61 secondary efficacy endpoints 61 receiving highly emetogenic 61 achieved sustained virological 61 nodular partial response 61 Peg IFN 61 μg dose 61 receiving VICTRELIS 61 decitabine 61 dose cytarabine 61 serum HCV RNA 61 p = NS 61 ribavirin RBV 61 chemoradiation therapy 61 urate lowering therapy 61 statistical significance p 61 #mg QD [001] 61 linaclotide treated 61 abacavir lamivudine 61 #mg/day [002] 61 ALT elevation 61 IBDQ 61 infliximab monotherapy 61 REYATAZ r 61 INC# 61 FFNS 61 atheroma volume 61 atazanavir ritonavir 61 febrile neutropenia 61 aminotransferase elevations greater 61 #mg/day [001] 61 ritonavir boosted 61 mL/min/#.# m 2 61 Primary endpoints 61 infliximab 61 Rate ORR 61 TMC# r 61 locoregional disease 61 mean baseline HbA1c 61 mcg mL 61 baseline A1C 60 budesonide pMDI 60 serum phosphorus 60 DOXIL 60 secondary endpoint 60 mITT population 60 alanine aminotransferase 60 briakinumab 60 Score DAS# 60 active comparator 60 Pemetrexed 60 ATACAND 60 mCi kg 60 hemoglobin A1c HbA1c 60 NATRECOR R 60 secondary efficacy endpoint 60 AUA Symptom Score 60 mesalamine granules 60 HbA 1c levels 60 μmol L 60 primary patency 60 Solid Tumors 60 peginterferon 60 KRAS mutations occur 60 metastatic CRC 60 HBeAg 60 pomalidomide 60 tamsulosin 60 refractory AML 60 serum urate levels 60 efavirenz EFV 60 urinary N telopeptide 60 MoxDuo TM IR 60 Non inferiority 60 MACCE 60 follicular lymphomas 60 Traficet EN 60 apremilast 60 plus COPEGUS 60 adjunctive ABILIFY 60 steroid dexamethasone 60 Betaferon R 60 rizatriptan 60 median survivals 60 amoxicillin clavulanate 60 mcg linaclotide 60 abnormal p# biomarker 60 Pred Forte 60 VELCADE melphalan 60 COPAXONE R 60 Secondary endpoints included 60 severe exacerbations 60 ng dL 60 efficacy endpoint 60 anthracycline taxane 60 Hazard Ratio 60 x ULN 60 NYHA functional class 60 glycosylated hemoglobin 60 Elitek 60 daily Infergen 60 atorvastatin #mg 60 serum clusterin levels 60 HbA1c levels 60 generalized edema 60 APTIVUS R 60 plus ribavirin 60 partial remissions 60 dacarbazine 60 highly emetogenic 60 laboratory abnormalities 60 prespecified 60 gout flares 60 Adalimumab 60 periprocedural 60 HbA1c 60 daunorubicin 60 Pegasys peginterferon alfa 2a 60 abdominal pain abdominal discomfort 60 TNSS 60 #mg/m# [002] 60 q8h 60 PEG IFN 60 lamivudine monotherapy 60 Durezol 60 FOLFOX4 alone 60 oblimersen 60 methotrexate MTX 60 #mg BID [003] 60 CSBMs 60 ARIXTRA 60 TEAEs 60 q#h 60 STELARA 60 receiving prophylactic anticoagulation 60 NATRECOR ® 60 demonstrated clinically meaningful 60 posaconazole 60 SCIg 60 Thrombolysis 60 hemoglobin A1c levels 60 lamivudine refractory patients 60 IU mL 60 #mg dose [003] 60 mEq L 60 events AEs 59 GOUT 59 nab paclitaxel 59 resected pancreatic cancer 59 scores TNSS 59 HCV RESPOND 2 59 recurrent VTE 59 zonisamide SR 59 Zometa hazard 59 μg kg 59 tipranavir 59 Lucentis monotherapy 59 posttreatment 59 LVEF 59 dosing cohort 59 #.#mg/dL 59 IOP lowering 59 ibandronate 59 mg m² 59 galiximab 59 bosentan 59 Brief Psychiatric 59 CNS LS 59 relapsed refractory multiple myeloma 59 HbA1C 59 iPTH 59 alicaforsen enema 59 peginterferon alfa 2b 59 estimated glomerular filtration 59 teriflunomide 59 fasting plasma glucose 59 alfa 2a 59 low dose Iluvien 59 hepatitis C genotype 59 mycophenolate mofetil 59 DMARD 59 sirolimus eluting stent 59 colesevelam HCl 59 Pain Intensity 59 Fludara 59 Pegylated Liposomal Doxorubicin 59 Peginterferon Alfa 2a 59 HIV RNA 59 ABC/3TC 59 #mg/m# [001] 59 ertapenem 59 cells uL 59 lispro 59 angiographic outcomes 59 hematologic toxicity 59 aspartate aminotransferase AST 59 moderately emetogenic 59 noninferiority 59 abatacept 59 weekly CSBMs 59 LPV r 59 virological suppression 59 OGTT 59 alteplase 59 Operative mortality 59 null responders 59 virologic responses 59 Severity MSCS score 59 ara C 59 tiotropium 59 PEG Interferon alfa 59 recurrent GBM 59 #.#/#.# mmHg [001] 59 R0 resection 59 FOLFIRI 59 hours postdose 59 Raptiva r 59 low dose cytarabine 59 ARCALYST ® 59 heavily pretreated 59 mL/min/#.# m2 59 Peginterferon 59 mCRC patients 59 CSBM 59 spontaneous bowel movements 59 TPV r 59 postintervention 59 ejection fractions 59 ALND 59 CLL SLL 59 TAXUS p value 59 #mg doses [002] 59 CsA 59 #mg BID [002] 59 PSADT 59 Negative Syndrome 59 copies mL 59 prednisone prednisolone plus 59 cinacalcet 59 unfractionated heparin UFH 59 azacitidine 59 azacytidine 59 adenoma recurrence 59 dacarbazine DTIC 59 ACTEMRA 59 oral FTY# 59 Index CDAI score 59 quetiapine XR 59 CYPHER Stent 59 CHOP chemotherapy 59 gemcitabine carboplatin 59 low dose dexamethasone 59 IRLS 59 statistically significant p 59 % CI #.#-#.# [007] 59 prednisone prednisolone 59 BENICAR 59 invasive aspergillosis 59 Tolerability 59 interferon alfa 2b 59 serum uric acid 59 Taxus Stent 59 EDSS 59 rilonacept 59 INCB# [003] 59 rFVIIa 59 receiving ISENTRESS 59 Platelet counts 59 UPDRS scores 59 International Prostate Symptom 59 docetaxel chemotherapy 59 Viread Emtriva SUSTIVA 59 hip BMD 59 Ceplene/IL-2 59 events SAEs 59 treat NNT 59 oral rivaroxaban 59 serum phosphorous 59 Cimzia ® 59 DLQI 59 Folfox 59 Acute Ischemic Stroke 59 X ULN 59 Kaplan Meier analysis 59 timepoints 59 HCV SPRINT 59 azilsartan medoxomil 59 receiving SIMPONI 59 Tarceva TM 59 metastatic RCC 59 primary endpoint 59 MADRS 59 NLX P# 58 Natalizumab 58 cytogenetic responses 58 TORISEL 58 baseline FEV 58 arterial thromboembolic events 58 nasal symptom 58 mg q#h 58 adalimumab Humira 58 tapentadol IR 58 perioperative mortality 58 pT2 58 insulin detemir 58 Sustained Virological Response 58 clinically meaningful improvements 58 Score TOS 58 postoperative chemotherapy 58 ng dl 58 imiquimod cream 58 dose cohort 58 locoregional recurrence 58 Tipranavir 58 dose cohorts 58 protease inhibitor PI 58 primary efficacy endpoints 58 RGT arm 58 dose dexamethasone 58 mRS 58 nondiabetic patients 58 plasma uric acid 58 mg Lucentis 58 dose clopidogrel 58 rosuvastatin #mg 58 plus OBT 58 mg simvastatin 58 recurrent glioblastoma multiforme 58 Copegus ribavirin 58 heavily pretreated patients 58 HBV DNA levels 58 febuxostat 58 ug dose 58 HOMA IR 58 etanercept 58 dalteparin 58 COMBIVIR 58 pegylated interferon alfa 2b 58 Score DAS 58 postoperative mortality 58 radiographic progression 58 PRECiSE 58 receiving INTRON 58 venlafaxine XR 58 dosed intravenously 58 BPH Symptom Score 58 paliperidone ER 58 dosage regimens 58 ALT normalization 58 β blockers 58 virologic breakthrough 58 Treatment Naive Patients 58 progression TTP 58 inflammatory lesions 58 PREZISTA ritonavir 58 lymphocytosis 58 rapid virological response 58 UPDRS motor 58 tiotropium bromide 58 DAPT 58 prospectively stratified 58 STELARA ® 58 retinal thickness 58 mg RDEA# 58 NPH insulin 58 HbA 1C 58 FOLFIRINOX 58 dose escalation phase 58 Disease Activity 58 creatinine ratio 58 titrated glipizide 58 HbA1C levels 58 viral suppression 58 balsalazide 58 mitoxantrone 58 PASI 58 aspartate aminotransferase 58 CLARITY study 58 estramustine 58 mg eq 58 nonresponders 58 baminercept 58 interferon ribavirin 58 doxazosin 58 transaminases 58 Ramipril 58 mmol l 58 PANSS 58 Virologic 58 neoadjuvant chemotherapy 58 pharmacokinetic PK profile 58 HBeAg positive 58 AEGR 58 GLIADEL R Wafer 58 hypokalemia 58 RAPAFLO R 58 nonvertebral fractures 58 preoperative chemotherapy 58 doxorubicin docetaxel 58 Solid Tumors RECIST 58 serum potassium 58 glycated hemoglobin HbA1c 58 elotuzumab 58 Events MACE 58 virologic 58 dosing cohorts 58 albumin excretion rate 58 acromegalic patients 58 bronchodilation 58 neutrophil counts 58 glycosylated hemoglobin HbA1c 58 bendamustine 58 Secondary endpoints include 58 nucleoside naive 58 mean serum phosphorus 58 subtrochanteric 58 UACR 58 benazepril 58 TNF antagonist 58 FluCAM arm 58 statin monotherapy 58 antiretroviral naive 58 Cimzia TM 58 mmHg diastolic 58 Knodell necroinflammatory score 58 ADAS Cog 58 hemoglobin concentrations 58 NNT = 58 Montgomery Åsberg Depression 58 Castration Resistant Prostate Cancer 58 pimecrolimus cream 58 biochemical recurrence 58 neoadjuvant therapy 58 Myocardial Infarction Study 58 Alzheimer Disease Assessment 58 nicardipine 58 transaminase elevations 58 ximelagatran 58 mg/m2 IV 58 epoetin alpha 58 entecavir 58 serum phosphate levels 58 aldosterone antagonists 58 pegylated interferon alfa 2a 58 salmeterol fluticasone propionate 58 tumor shrinkage 58 SELENA SLEDAI 58 postprocedure 58 RAPAFLO 58 interferon alfa 2a 58 fluvastatin 58 mm Stent 58 prior chemotherapy regimens 58 otamixaban 58 Infusion Reactions Severe 58 clinically evaluable patients 57 creatinine clearance 57 5-FU/LV 57 tacrolimus ointment 57 mg/m2 57 angiographic restenosis 57 haematologic 57 Median survival 57 undetectable virus HCV 57 Telbivudine 57 saline placebo 57 RE LY ® 57 Target Lesion Revascularization TLR 57 YERVOY 57 genotypic resistance 57 Aflibercept 57 Unified Parkinson Disease 57 Partial Response 57 elevated creatinine 57 PRADAXA 57 pegylated interferon 57 nadolol 57 Sustained Virologic Response 57 glimepiride 57 mg p = 57 canakinumab 57 receiving APTIVUS r 57 noninferior 57 #Gy 57 Primary Endpoint 57 liposome injection 57 postvaccination 57 GnRH agonist 57 lumbar spine bone 57 xanthine oxidase inhibitor 57 Oral Fingolimod 57 stage IIIb IV 57 thromboembolic events 57 RECIST 57 hemagglutination inhibition 57 HBV DNA 57 Relapsing Multiple Sclerosis 57 virological failure 57 permanently discontinue Vectibix 57 placebo 57 -#.# log# copies mL 57 oral levofloxacin 57 relapsed CLL 57 sham injections 57 somatostatin analog 57 doxorubicin cyclophosphamide 57 ALT flares 57 SPIRIT FIRST 57 ribavirin therapy 57 HUMIRA achieved PASI 57 biologic DMARD 57 AVODART 57 dopamine partial agonist 57 CYPHER ® Stent 57 macroalbuminuria 57 Golimumab 57 rimonabant #mg 57 HI titers 57 Retreatment 57 plasma cortisol 57 postmenopausal osteoporotic women 57 ascending dose 57 cabazitaxel 57 ruboxistaurin 57 preoperatively 57 #mg q8h 57 tenofovir emtricitabine 57 carboplatin paclitaxel 57 RAPTIVA 57 splenectomized 57 antibody titer 57 p = .# [002] 57 abciximab 57 ALT elevations 57 neutropaenia 57 XELOX 57 UPDRS 57 melphalan prednisone 57 Decitabine 57 β blocker 57 APTIVUS 57 plus prednisone prednisolone 57 LANTUS R 57 Score IPSS 57 serum ALT 57 REYATAZ R 57 ELOXATIN 57 Complete Response CR 57 platelet inhibition 57 calculated creatinine clearance 57 RESIST studies 57 evaluating tivozanib 57 IV bolus 57 troponin T 57 concomitant medications 57 Viral load 57 neoadjuvant 57 PASI score 57 EURIDIS 57 mg tid 57 alpha 2a 57 serum cortisol 57 peg IFN 57 microg 57 #mg dose [001] 57 Cethromycin 57 Lantus ® 57 metastatic GIST 57 composite endpoint 57 irbesartan 57 intermittent dosing 57 lacosamide 57 humanized interleukin 6 57 SSRI citalopram 57 HAMD 57 quetiapine 57 Follicular Lymphoma 57 XIENCE V demonstrated 57 fluticasone 57 AA Amyloidosis 57 hyperphenylalaninemia HPA due 57 non splenectomized 57 paraprotein 57 EBMT criteria 57 histologically confirmed 57 Major Adverse Cardiac 57 CI -#.# 57 CK # plasma concentrations 57 QD dosing 57 platinum refractory 57 baseline PASI 57 systemic embolism 57 mg d 57 HCV RNA 57 Helicobacter pylori eradication 57 PEGASYS ® 57 Stent thrombosis 57 seroconversion 57 SBMs 57 infusional 5-FU/LV 57 refractory NSCLC 57 FOLPI regimen 57 elagolix 57 symptomatic VTE 57 â ‰ ¥ 57 chemoradiotherapy 57 mcg kg REBETOL 57 tumor progression TTP 57 femoral neck BMD 57 nucleoside naive patients 57 #mg/kg [002] 57 RoACTEMRA 57 baseline FEV1 57 COZAAR 57 gemcitabine cisplatin 57 Omacetaxine 57 NEVO ™ 57 mitoxantrone plus 57 infliximab therapy 57 neostigmine 57 ACE inhibitor ramipril 57 Dasatinib 57 Median progression 57 nonsignificant difference 57 Secondary endpoints 57 INVEGA ® 57 sUA levels 57 uncorrected visual acuity 57 aminotransferases 57 reduce serum phosphate 57 rimonabant #mg/day 57 g dl 57 icatibant 57 telbivudine 57 STN stimulation 57 pharmacokinetic characteristics 57 RRMS patients 57 p ≤ 57 aged ≥ 57 allogeneic SCT 57 ketoconazole 57 standard chemotherapy regimen 57 TAXUS Stent 56 Dextofisopam 56 analgesic efficacy 56 postoperatively 56 leukocyte count 56 limiting toxicity 56 paclitaxel cisplatin 56 carboplatin chemotherapy 56 thromboembolic 56 ECOG PS 56 mg/# h 56 HCV Genotype 56 mg kg hr 56 pegIFN 56 -#.# ± [002] 56 neoadjuvant radiation 56 Hb A1c 56 LymphoStat B 56 chronic HCV infection 56 CIN3 56 treatment naive genotype 56 GSK# [001] 56 STRIDE PD 56 dacarbazine chemotherapy 56 graft dysfunction 56 ADHF 56 p = #.# [003] 56 follicular NHL 56 MAGE A3 ASCI 56 TURBT 56 nephrotoxicity 56 mg subcutaneously 56 plasma leptin 56 Kaplan Meier estimate 56 platelet reactivity 56 FIRMAGON 56 MabCampath 56 conjunctival hyperemia 56 cytarabine daunorubicin 56 peginterferon alfa 56 Betaferon ® 56 blood phenylalanine Phe 56 forodesine 56 blood Phe 56 GAMMAGARD 56 mCi m 2 56 sorafenib tablets 56 nadroparin 56 IELT 56 glycated hemoglobin 56 chronic angina 56 serum aminotransferase levels 56 Percutaneous Coronary Intervention 56 plus gemcitabine 56 bivalirudin monotherapy 56 sunitinib 56 mild renal insufficiency 56 hypophosphatemia 56 stage IIIB 56 reinfarction 56 detemir 56 LEXIVA 56 hypomagnesemia 56 ISENTRESS 56 KAPIDEX 56 telaprevir dosed 56 neuropathy sensory 56 L PPDS 56 asthma exacerbation 56 azathioprine monotherapy 56 sitagliptin 56 NIHSS score 56 sargramostim 56 clinically evaluable population 56 pain palliation 56 T2 lesions 56 clinically meaningful 56 mean baseline A1C 56 Cmax 56 deep venous thromboses 56 mg doses 56 HER2 expression 56 serum creatinine levels 56 underwent resection 56 riociguat